留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

药物性肝损伤肝移植治疗进展

王砚伟, 梁雨荣. 药物性肝损伤肝移植治疗进展[J]. 器官移植, 2022, 13(3): 338-343. doi: 10.3969/j.issn.1674-7445.2022.03.009
引用本文: 王砚伟, 梁雨荣. 药物性肝损伤肝移植治疗进展[J]. 器官移植, 2022, 13(3): 338-343. doi: 10.3969/j.issn.1674-7445.2022.03.009
Wang Yanwei, Liang Yurong. Research progress on liver transplantation for drug-induced liver injury[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 338-343. doi: 10.3969/j.issn.1674-7445.2022.03.009
Citation: Wang Yanwei, Liang Yurong. Research progress on liver transplantation for drug-induced liver injury[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 338-343. doi: 10.3969/j.issn.1674-7445.2022.03.009

药物性肝损伤肝移植治疗进展

doi: 10.3969/j.issn.1674-7445.2022.03.009
基金项目: 

吴阶平医学基金 320.6750.11010

详细信息
    作者简介:
    通讯作者:

    梁雨荣, Email: yurongliang@hotmail.com

  • 中图分类号: R617, R575

Research progress on liver transplantation for drug-induced liver injury

More Information
  • 摘要: 药物性肝损伤(DILI)是由临床常用的某些药物、中草药或膳食补充剂引起的一种坏死性炎症性肝病,严重时可能会导致急性肝衰竭,如果不进行肝移植,病死率可达80%。如何把握肝移植的指征非常关键,一些预后评分系统已被开发用于帮助临床医师决定哪些患者需要行紧急肝移植,如国王学院标准(KCC)和终末期肝病模型(MELD)评分,但这些方法年代久远、缺乏更新,因此有学者提出一些新型的评分系统,如急性生理学及慢性健康状况评分Ⅱ(APACHE Ⅱ)及序贯器官衰竭评分(SOFA),为肝移植评估提供了新的思路。紧急肝移植作为药物性急性肝衰竭的重要治疗措施,极大地提高了患者的生存率。本文总结了DILI的分型、临床诊断、肝移植评估及预后,旨在为DILI的肝移植治疗提供参考。

     

  • [1] 寇晓彤, 李琦, 陈畅. 药物诱导的肝损伤研究现状[J]. 中国临床药理学杂志, 2021, 37(21): 2981-2984. DOI: 10.13699/j.cnki.1001-6821.2021.21.028.

    KOU XT, LI Q, CHEN C. Research progress of drug induced liver injury[J]. Chin J Clin Pharmacol, 2021, 37(21): 2981-2984. DOI: 10.13699/j.cnki.1001-6821.2021.21.028.
    [2] GERMANI G, BATTISTELLA S, ULINICI D, et al. Drug induced liver injury: from pathogenesis to liver transplantation[J]. Minerva Gastroenterol (Torino), 2021, 67(1): 50-64. DOI: 10.23736/S2724-5985.20.02795-6.
    [3] CHAYANUPATKUL M, SCHIANO TD. Acute liver failure secondary to drug-induced liver injury[J]. Clin Liver Dis, 2020, 24(1): 75-87. DOI: 10.1016/j.cld.2019.09.005.
    [4] 杨婉娜, 谢雯. 药物性肝损伤的临床表现和分型[J]. 临床肝胆病杂志, 2021, 37(11): 2525-2529. DOI: 10.3969/j.issn.1001-5256.2021.11.004.

    YANG WN, XIE W. Clinical manifestations and typing of drug-induced liver injury[J]. J Clin Hepatol, 2021, 37(11): 2525-2529. DOI: 10.3969/j.issn.1001-5256.2021.11.004.
    [5] TILLMANN HL, ROCKEY DC. Signatures in drug-induced liver injury[J]. Curr Opin Gastroenterol, 2020, 36(3): 199-205. DOI: 10.1097/MOG.0000000000000636.
    [6] CHANG L, XU D, ZHU J, et al. Herbal therapy for the treatment of acetaminophen-associated liver injury: recent advances and future perspectives[J]. Front Pharmacol, 2020, 11: 313. DOI: 10.3389/fphar.2020.00313.
    [7] SIMMONS OL, MEINZER C, RULE J, et al. Liver transplantation for acetaminophen-induced acute liver failure: role of psychiatric comorbidity in listing decisions and outcomes[J]. Dig Dis Sci, 2020, 65(6): 1861-1868. DOI: 10.1007/s10620-019-05901-2.
    [8] HASSAN A, FONTANA RJ. The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Liver Int, 2019, 39(1): 31-41. DOI: 10.1111/liv.13931.
    [9] GU R, LIANG A, LIAO G, et al. Roles of co-factors in drug-induced liver injury: drug metabolism and beyond[J]. Drug Metab Dispos, 2022, DOI: 10.1124/dmd.121.000457[Epub ahead of print].
    [10] AHMAD J, ODIN JA. Epidemiology and genetic risk factors of drug hepatotoxicity[J]. Clin Liver Dis, 2017, 21(1): 55-72. DOI: 10.1016/j.cld.2016.08.004.
    [11] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 实用肝脏病杂志, 2017, 20(2): 257-274. DOI: 10.3969/j.issn.1672-5069.2017.02.039.

    YU LC, MAO YM, CHEN CW. Guidelines for diagnosis and treatment of drug-induced liver injury[J]. J Pract Hepatol, 2017, 20(2): 257-274. DOI: 10.3969/j.issn.1672-5069.2017.02.039.
    [12] 马晓瑞, 李红霞, 马利. 348例药物性肝损害的临床分析[J]. 西安交通大学学报(医学版), 2021, 42(6): 909-914. DOI: 10.7652/jdyxb202106020.

    MA XR, LI HX, MA L. Clinical analysis of 348 cases of drug-induced liver damage[J]. J Xi'an Jiaotong Univ(Med Sci), 2021, 42(6): 909-914. DOI: 10.7652/jdyxb202106020.
    [13] GARCIA-CORTES M, ROBLES-DIAZ M, STEPHENS C, et al. Drug induced liver injury: an update[J]. Arch Toxicol, 2020, 94(10): 3381-3407. DOI: 10.1007/s00204-020-02885-1.
    [14] REAL M, BARNHILL MS, HIGLEY C, et al. Drug-induced liver injury: highlights of the recent literature[J]. Drug Saf, 2019, 42(3): 365-387. DOI: 10.1007/s40264-018-0743-2.
    [15] DELIRE B, DE MARTIN E, MEUNIER L, et al. Immunotherapy and gene therapy: new challenges in the diagnosis and management of drug-induced liver injury[J]. Front Pharmacol, 2022, 12: 786174. DOI: 10.3389/fphar.2021.786174.
    [16] 丁超峰, 高晟, 郑树森. 药物性急性肝衰竭行肝移植治疗的预后因素探讨[J/CD]. 中华移植杂志(电子版), 2020, 14(4): 268-271. DOI: 10.3877/cma.j.issn.1674-3903.2020.04.017.

    DING CF, GAO S, ZHENG SS. Prognostic factors of liver transplantation for patients with drug induced acute liver failure[J/CD]. Chin J Transplant (Electr Edit), 2020, 14(4): 268-271. DOI: 10.3877/cma.j.issn.1674-3903.2020.04.017.
    [17] DONDORF F, CRONER RS, TAUTENHAHN HM, et al. Liver transplant due to flupirtine-induced acute liver failure[J]. Exp Clin Transplant, 2020, 18(4): 481-484. DOI: 10.6002/ect.2019.0297.
    [18] LEE JE, KWAK KH. A liver transplant recipient with possible bupivacaine-induced liver injury caused by intra-articular injection after total knee arthroplasty: a case report[J]. Medicine (Baltimore), 2018, 97(38): e12481. DOI: 10.1097/MD.0000000000012481.
    [19] YEBOAH-KORANG A, MEMON A, PATEL N, et al. Impact of prior drug allergies on the risk, clinical features, and outcomes of idiosyncratic drug-induced liver injury in adults[J]. Dig Dis Sci, 2022, DOI: 10.1007/s10620-022-07403-0[Epub ahead of print].
    [20] WEBER S, WOISCHKE C, DENK G, et al. Novel predictors for liver transplantation or death in drug-induced acute liver failure[J]. Eur J Gastroenterol Hepatol, 2022, 34(4): 422-425. DOI: 10.1097/MEG.0000000000002272.
    [21] MCPHAIL MJ, FARNE H, SENVAR N, et al. Ability of King's College criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure: a Meta-analysis[J]. Clin Gastroenterol Hepatol, 2016, 14(4): 516-525. DOI: 10.1016/j.cgh.2015.10.007.
    [22] ANAND AC, NIGHTINGALE P, NEUBERGER JM. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria[J]. J Hepatol, 1997, 26(1): 62-68. DOI: 10.1016/s0168-8278(97)80010-4.
    [23] KHANAM A, KOTTILIL S. Acute-on-chronic liver failure: pathophysiological mechanisms and management[J]. Front Med (Lausanne), 2021, 8: 752875. DOI: 10.3389/fmed.2021.752875.
    [24] KIM WR, MANNALITHARA A, HEIMBACH JK, et al. MELD 3.0: the model for end-stage liver disease updated for the modern era[J]. Gastroenterology, 2021, 161(6): 1887-1895. DOI: 10.1053/j.gastro.2021.08.050.
    [25] CHOLONGITAS E, THEOCHARIDOU E, VASIANOPOULOU P, et al. Comparison of the sequential organ failure assessment score with the King's College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure[J]. Liver Transpl, 2012, 18(4): 405-412. DOI: 10.1002/lt.23370.
    [26] BJÖRNSSON ES. Clinical management of patients with drug-induced liver injury (DILI)[J]. United European Gastroenterol J, 2021, 9(7): 781-786. DOI: 10.1002/ueg2.12113.
    [27] SÁEZ-GONZÁLEZ E, CONDE I, DÍAZ-JAIME FC, et al. Iberogast-induced severe hepatotoxicity leading to liver transplantation[J]. Am J Gastroenterol, 2016, 111(9): 1364-1365. DOI: 10.1038/ajg.2016.260.
    [28] MINDIKOGLU AL, MAGDER LS, REGEV A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database[J]. Liver Transpl, 2009, 15(7): 719-729. DOI: 10.1002/lt.21692.
    [29] BERNAL W, CROSS TJ, AUZINGER G, et al. Outcome after wait-listing for emergency liver transplantation in acute liver failure: a single centre experience[J]. J Hepatol, 2009, 50(2): 306-313. DOI: 10.1016/j.jhep.2008.09.012.
    [30] DAWWAS MF, GIMSON AE, LEWSEY JD, et al. Survival after liver transplantation in the United Kingdom and Ireland compared with the United States[J]. Gut, 2007, 56(11): 1606-1613. DOI: 10.1136/gut.2006.111369.
    [31] AU KP, CHAN SC, CHOK KS, et al. Clinical factors affecting rejection rates in liver transplantation[J]. Hepatobiliary Pancreat Dis Int, 2015, 14(4): 367-373. DOI: 10.1016/s1499-3872(15)60391-5.
  • 加载中
图(1)
计量
  • 文章访问数:  301
  • HTML全文浏览量:  165
  • PDF下载量:  92
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-24
  • 网络出版日期:  2022-04-29
  • 刊出日期:  2022-05-15

目录

    /

    返回文章
    返回